Takaoka, Japan

Koichi Wada


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1998-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Koichi Wada: Innovator in Anticoagulant Research

Introduction

Koichi Wada is a notable inventor based in Takaoka, Japan. He has made significant contributions to the field of anticoagulant research, particularly through his innovative work on hirudin variants. With a total of two patents to his name, Wada's inventions focus on enhancing anti-thrombin and anti-platelet activities.

Latest Patents

Wada's latest patents include advancements in anticoagulant hirudin variants and methods for their production. These inventions relate to hirudin variants that exhibit high anti-thrombin and anti-platelet activity. The patents detail methods for producing these variants, which include sulfating the hydroxyl group of tyrosine residues. The resulting anti-coagulants utilize these hirudin variants as active ingredients, showcasing Wada's commitment to improving therapeutic options in medicine.

Career Highlights

Throughout his career, Koichi Wada has worked with prominent companies such as Fuji Yakuhin Kogyo Kabushiki Kaisha and Nippon Mining Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biochemistry and pharmaceuticals. Wada's work has been instrumental in advancing the understanding and application of anticoagulants.

Collaborations

Wada has collaborated with notable colleagues, including Eriko Nukui and Masaharu Nakano. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of anticoagulant research.

Conclusion

Koichi Wada's contributions to the development of anticoagulant hirudin variants highlight his role as an influential inventor in the medical field. His patents and collaborations reflect a dedication to advancing healthcare solutions. Wada's work continues to impact the landscape of anticoagulant therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…